Abstract. Broussonetia kazinoki (BK) has been used as a traditional medicine to improve vision, as well as for inflammatory and infectious diseases. In the present study, we investigated the effects and molecular mechanism of the ethanolic extract of BK on cell proliferation, migration and tubular formation in vascular endothelial growth factor-A (VEGF-A)-treated human umbilical vein endothelial cells. BK treatment inhibited VEGF-A-stimulated endothelial cell proliferation through the downregulation of cell cycle-related proteins including cyclin-dependent kinases and cyclins. Moreover, BK treatment suppressed cell migration and tubular formation in response to VEGF-A. These anti-angiogenic activities of BK were associated with the inactivation of mitogenic signaling pathways including extracellular signal-regulated kinase, Akt and p70 S6K , and the subsequent downregulation of VEGFR-2 and matrix metalloproteinase-2. Taken together, these findings suggest further evaluation and development of BK as a potential therapeutic agent for the treatment and prevention of angiogenesis-related diseases including cancer.
Introduction
Angiogenesis, the formation and recruitment of new blood vessels, is known to play important roles in cancer growth and progression, and is regulated by the production of several angiogenic and anti-angiogenic factors (1, 2) . Among angiogenic factors, vascular endothelial growth factor-A (VEGF-A) and VEGF receptor-2 (VEGFR-2) signaling pathways stimulate the secretion and activation of matrix metalloproteinases (MMPs) in endothelial cells which result in cell proliferation, migration and survival, and are widely appreciated as the therapeutic targets for a variety of angiogenesis-related diseases. The central role of the VEGF-A/VEGFR-2 in this process is evidenced by the development and approval of pegaptanib and ranibizumab for age-related macular degeneration as well as bevacizumab and sunitinib for cancer treatment (3) (4) (5) . However, current approved anti-angiogenic drugs frequently lead to drug resistance and recurrence of cancer growth and progression. Thus, further understanding of the molecular mechanisms and targets of angiogenic responses may help to develop potential therapeutic strategies for the treatment of cancer as well as angiogenesis-related diseases.
MMPs belong to a family of zinc-dependent endopeptidases and are responsible for tissue remodeling by selective proteolytic degradation, resulting in the promotion of cancer growth and progression through alterations of cell adhesion, migration, epithelial to mesenchymal transition, tumor angiogenesis and release of growth factors (6) (7) (8) . These MMPs are regulated by their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs) (9, 10) . In addition to MMP-inhibitory activity, TIMPs have been reported to regulate cell growth, migration and differentiation through the MMP-independent mechanism (11) (12) (13) (14) . Identification of molecular mechanisms and targets in regulating expression and activities of MMPs and TIMPs within the tumor microenvironment has become an attractive strategy for therapeutic intervention in cancer growth and progression.
Broussonetia kazinoki (BK) Siebold (Moraceae) has been used as a traditional medicine for the amelioration of vision, inflammatory and infectious diseases as well as a material for production of paper in Northeastern Asia. anti-inflammatory, anti-allergic and anticancer activities (15) (16) (17) (18) (19) . However, the effects and molecular mechanisms of BK on angiogenesis remain unknown. In the present study, we evaluated the effects and signaling pathways of BK on proliferation, migration and tubular formation in human umbilical vein endothelial cells. 
Materials and methods

Cell
Preparation of Broussonetia kazinoki (BK) extract.
The ethanol extract was prepared by mixing 100 g of twigs of BK with 1 liter of 100% ethanol and stirring for 72 h. The extract was then filtered through a filter paper (Advantec No. 1; Toyo Roshi Kaisha, Ltd., Tokyo, Japan), and the filtrate was concentrated using a rotary evaporator (Tokyo Rikakikai Co., Ltd., Tokyo, Japan) at 40˚C under vacuum. The yield of the dried extract was ~1.37%.
Cell viability and proliferation assay. HuVECs, plated on 6-well plates (1x10 5 cells/well; BD Biosciences, Bedford, MA, uSA), were serum-starved for 14 h to synchronize cells in the G 1 /G 0 phase of the cell cycle, and pretreated with BK (0.1-10 µg/ml) for 30 min in the presence or absence of PD98059 (25 µM), LY294002 (10 µM) or rapamycin (50 nM) as indicated, and then incubated with VEGF-A (10 ng/ml) for 24 h. Following culture for 24 h, cell viability was determined by a Muse™ cell analyzer using a cell count and viability assay kit (Merck Millipore), and the cell proliferation was quantified as previously described (20) (21) (22) . The results from triplicate determinations (mean ± standard deviation) are presented as the number of cells per culture.
Western blot analysis. HuVECs in 100-mm dishes (1x10 6 cells/dish; BD Biosciences) were serum-starved for 14 h in endothelial cell basal medium (EBM-2; Lonza) and replaced with fresh media, followed by treatments for different time-points, as indicated in the figure legends, at 37˚C. The cells were rinsed twice with ice-cold phosphate-buffered saline (PBS) and lysed by incubation in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EDTA, 100 µg/ml 4-(2-aminoethyl)benzenesulfonyl fluoride, 10 µg/ml aprotinin, 1 µg/ml pepstatin A, 0.5 µg/ml leupeptin, 80 mM β-glycerophosphate, 25 mM sodium fluoride and 1 mM sodium orthovanadate for 30 min at 4˚C. Cell lysates were clarified at 12,500 x g for 20 min at 4˚C, and the supernatants were subjected to western blot analysis as previously described (23, 24) . All the western blots were performed in triplicate and representative gels were shown.
Migration assay. Cell migration was quantified in the in vitro wound-healing assay as previously described (25, 26) . Cells were plated on 48-well plates (4x10 4 cells/well), grown to confluence, and a single wound was created in the center of the cell monolayer by the gentle removal of the attached cells with a sterile plastic pipette tip. Following serum starvation with EBM-2 for 2 h, the cells were pretreated with BK (0.1-10 µg/ml) for 30 min, followed by VEGF-A (10 ng/ml) stimulation for 16 h. The cells were fixed with methanol, and then stained with 0.04% Giemsa solution (Sigma-Aldrich). The migration of the cells into the wound was observed using images captured at the indicated time-points.
Tube formation assays. Matrigel ® basement membrane matrix (10.4 mg/ml; BD Biosciences) was thawed overnight at 4˚C, and each well of pre-chilled 24-well plates was coated with 200 µl Matrigel ® and then incubated at 37˚C for 30 min. Following serum starvation with EBM-2 for 2 h, the cells (4x10 4 cells/ml) were added to Matrigel ® -coated plates and pretreated with BK (0.1-10 µg/ml) for 30 min, followed by VEGF-A (10 ng/ml) for 6 h. Tube formation was observed with an Olympus CKX41 inverted microscope (CAchN 10/0.25php objective) and ToupTek Toupview software (version x86, 3.5.563; Hangzhou ToupTek Photonics Co., Ltd., Zhejiang, China).
Zymogram analysis. Activities of MMPs were measured by zymography (27, 28) . Aliquots of conditioned medium collected from HuVECs treated with BK (10 µg/ml) and VEGF-A (10 ng/ml) for 16 h were diluted in sample buffer, and applied to 8% polyacrylamide gels containing 1 mg/ml gelatin (Sigma-Aldrich) as a substrate. After electrophoresis, the gels were incubated in 2.5% Triton X-100 for 1 h to remove SDS and allow the re-naturalization of MMPs, and then incubated in developing buffer containing 50 mM Tris-HCl (pH 7.5), 10 mM CaCl 2 , and 150 mM NaCl for 16 h at 37˚C. The gels were stained with 0.5% Coomassie brilliant blue R-250 in 30% methanol-10% acetic acid for 3 h and followed by destaining with 30% methanol-10% acetic acid. Gelatinolytic activities were detected as unstained bands against the background of the Coomassie blue-stained gelatin.
Statistical analysis. Statistical analysis was performed using the Student's t-test, and was based on at least three different experiments. The results were considered to be statistically significant when P<0.05.
Results
BK suppresses VEGF-A-stimulated endothelial cell proliferation by modulating the expression of cell cycle-related
proteins. We first examined the ability of BK to regulate proliferation in HuVECs. BK treatment suppressed VEGF-Astimulated cell proliferation in a dose-dependent manner (Fig. 1A) and did not alter cell viability (Fig. 1B) , suggesting that BK inhibition of cell proliferation is not mediated by the induction of apoptosis or cytotoxicity. Based on these findings, we examined the regulatory effect of BK on cell cycle progression by analyzing the changes of cyclin-dependent kinases (Cdks) and cyclins. Cell cycle progression requires activation of Cdks through formation with cyclins and subsequent phosphorylation of retinoblastoma protein (pRb) (29) . As shown in 
BK inhibits VEGF-A-stimulated endothelial cell migration
and capillary structure formation. Endothelial cell migration and tubular formation are coordinately controlled by the interactions from ECM molecules to the intracellular and intercellular components of cells, and play important roles in angiogenic responses associated with cancer growth and progression (2) . BK treatment dose-dependently inhibited VEGF-A-stimulated cell migration and tubular formation in HUVECs (Figs. 2 and 3) . Collectively, these findings suggested that the bioactive components from the ethanolic extracts of BK act on multiple targets and mechanisms involved in cell proliferation, migration and tubular formation, resulting in the regulation of angiogenic responses in vitro.
BK suppresses VEGFR-2 and MMP-2 expression in VEGF-Atreated HUVECs.
The expression and activation of VEGFR-2 and MMP-2 have been reported to promote angiogenic responses including endothelial cell proliferation, migration, invasion and tubular formation (1, 2, 30) . To understand the molecular mechanism underlying the regulatory effects of BK on endothelial cell proliferation, migration and tubular formation, we analyzed the changes in the expression of VEGFR-2, MMP-2 and TIMP-2, an endogenous inhibitor of MMPs, in VEGF-A-treated HuVECs. BK treatment markedly suppressed the VEGF-A-induced expression of VEGFR-2 and MMP-2 (Fig. 4A) . As shown in Fig. 4B , BK treatment also inhibited VEGF-A-induced activation of MMP-2 in conditioned medium of HuVECs. By contrast, the levels of TIMP-2 in HuVECs were not altered by VEGF-A or BK treatment (Fig. 4A) . Taken together, these findings indicates that the inhibitory effects of BK on endothelial cell proliferation, migration and tubular formation may be mediated at least in part through the suppression of VEGFR-2 and MMP-2 expression.
In vitro anti-angiogenic activities of BK are mediated through the inhibition of mitogenic signaling pathways and downregulation of VEGFR-2 and MMP-2.
To investigate the molecular mechanisms by which BK regulates endothelial cell responses, we examined the changes in the activation of signaling pathways including extracellular signal-regulated kinase (ERK), p38 mitogen-activated protein kinase (p38 MAPK ), phosphatidylinositol 3-kinase (PI3-K)/Akt and mammalian target of rapamycin (mTOR)/p70 S6K , which play pivotal roles in cell fate (31) . As shown in Fig. 5A , VEGF-A stimulation markedly increased the phosphorylation/activation of ERK, Akt and p70 S6K , but not that of p38 MAPK , when compared with unstimulated controls. By contrast, BK treatment significantly inhibited the VEGF-A-stimulated phosphorylation of ERK, Akt, and S6K in HuVECs. Pretreatment of cells with PD98059 (an inhibitor of the ERK pathway), LY294002 (an inhibitor of the PI3-K/Akt pathway) or rapamycin (an inhibitor of the mTOR/ p70 S6K pathway) suppressed the expression of VEGFR-2 and MMP-2 in response to VEGF-A stimulation, suggesting that BK may contain pharmacologically effective components similar to these inhibitors, and share the roles and mechanisms of action in regulating endothelial cell proliferation, migration and tubular formation (Fig. 5B) . Taken together, these findings demonstrated that the suppression of endothelial cell proliferation, migration and tubular formation by BK ethanol extracts might be mediated through the inactivation of VEGFR-2 downstream signaling pathways and subsequent downregulation of VEGFR-2 and MMP-2.
Discussion
Broussonetia kazinoki (BK) has been used as a traditional medicine for improving vision, as well as in inflammatory and infectious diseases. These applications are well supported by previous investigations that BK possesses bioactive phytochemicals such as isoprenylated and prenylated flavans to reduce inflammation (15, 17) . In addition to anti-inflammatory activity, BK has been reported to have cytotoxicity against several different cell lines including liver, cervical, oral, colon, lung and gastric cancer (18, 19, 32) . However, no effects and molecular mechanisms of BK on angiogenesis have been reported thus far.
VEGF-A/VEGFR-2 signaling pathways play pivotal roles in the formation and stability of blood vessels associated with cancer growth and progression (1, 3, 14, 30, 33) . These angiogenic responses induced by VEGF-A/VEGFR-2 signaling pathways include the secretion and activation of MMPs, resulting in the degradation of the extracellular matrix and remodeling of the tumor microenvironment. Thus, selective inhibition of VEGF-A/VEGFR-2 activation or downstream signaling pathways is appreciated as a potent strategy, compared to conventional chemotherapy.
To the best of our knowledge, in the present study, we have shown for the first time that the ethanol extract of BK inhibits VEGF-A-stimulated proliferation, migration and tubular formation in HuVECs. These anti-angiogenic activities of BK were found to be mediated through the inhibition of VEGF-Astimulated phosphorylation/activation of ERK, Akt and p70 S6K , the downstream targets in VEGFR-2 signaling pathways, and downregulation of VEGFR-2 and MMP-2 as evidenced by using pharmacological inhibitors such as PD98059, LY294002 and rapamycin.
In conclusion, our findings provide important insights into the roles and pharmacological efficacy of BK in regulation of angiogenesis. However, further investigation on the development of BK for the treatment of a variety of diseases associated with angiogenesis should be conducted.
